Remove Biosimilars Remove Drug Pricing Remove Prescription Filling
article thumbnail

Three strategies for managing loss of exclusivity successfully

pharmaphorum

Drug prices to plummet in wave of expiring patents”. Price decay after loss of brand exclusivity”. These are just three headlines that come up when you Google “drug patent expiry”. In late 2017, the FDA approved Admelog, Sanofi’s biosimilar of Humalog. “Patent losses could sink Allergan”.

article thumbnail

NHC Submits Comments to CMS RE CY 2026 Policy & Technical Changes to MA and Part D Proposed Rule

Putting Patients First Blog

Formulary Inclusion and Placement of Generics and Biosimilars The NHC supports CMS proposals to improve formulary practices by prioritizing access to generics, biosimilars, and other cost-effective medications in the Medicare Part D program.

article thumbnail

January 2025 Newsletter

Safe Biologics

This expansion continues a flawed policy that threatens innovation and jeopardizes patient access to critical treatments, including drugs vital for cancer treatment and popular new weight loss medications that have transformed the management of obesity and related conditions. Read the full statement here.